Potassium
drugOn this page
Summary
Potassium (CHEMBL1201290) is a phase-3 clinical-stage small molecule targeting KCNA1, KCNA3, and KCNA6; indicated across 3 conditions including hypertensive disorder and andersen-tawil syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Targets: 5 (KCNA1, KCNA3, KCNA6…)
- Indications: 3 conditions
- Clinical trials: 62
- Chemistry: K
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201290 |
| Name | Potassium |
| Type | Small molecule |
| Max phase | 3 |
| ChEBI | CHEBI:26216 |
| Molecular formula | K |
| InChIKey | ZLMJMSJWJFRBEC-UHFFFAOYSA-N |
SMILES: [K]
Pharmacological roles (ChEBI): macronutrient.
Other ChEBI roles (chemical / environmental): Saccharomyces cerevisiae metabolite.
Also known as: Potassium, POTASSIUM
Patent coverage: 3,313 distinct patent families (4,286 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| KCNA1 | Kv1.1 | 10.8 | 0% | Q09470 | |
| KCNA3 | Kv1.3 | 12 | 3.1% | P22001 | |
| KCNA6 | Kv1.6 | 9.8 | 0.1% | P17658 | |
| KCNA7 | Kv1.7 | 7.9 | 0.5% | Q96RP8 | |
| KCNC2 | Kv3.2 | 9.5 | 0.6% | Q96PR1 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 5 target gene(s): KCNA1, KCNA3, KCNA6, KCNA7, KCNC2.
Top Reactome pathways
7 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Neuronal System | 5 | KCNA1, KCNA3, KCNA6, KCNA7, KCNC2 |
| Potassium Channels | 5 | KCNA1, KCNA3, KCNA6, KCNA7, KCNC2 |
| Voltage gated Potassium channels | 5 | KCNA1, KCNA3, KCNA6, KCNA7, KCNC2 |
| Metabolism | 1 | KCNC2 |
| Integration of energy metabolism | 1 | KCNC2 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 1 | KCNC2 |
| Regulation of insulin secretion | 1 | KCNC2 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| action potential | 5 |
| protein homooligomerization | 5 |
| potassium ion transmembrane transport | 5 |
| monoatomic ion transport | 5 |
| potassium ion transport | 5 |
| monoatomic ion transmembrane transport | 5 |
| transmembrane transport | 5 |
| startle response | 1 |
| regulation of muscle contraction | 1 |
| neuroblast proliferation | 1 |
| cell communication by electrical coupling | 1 |
| magnesium ion homeostasis | 1 |
| neuronal action potential | 1 |
| hippocampus development | 1 |
| neuronal signal transduction | 1 |
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| hypertensive disorder | 1 | MONDO:0005044 | EFO:0000537 |
| Andersen-Tawil syndrome | 1 | MONDO:0008222 | Orphanet:37553 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 62.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 18 |
| Not specified | 16 |
| PHASE3 | 13 |
| PHASE4 | 8 |
| PHASE2/PHASE3 | 3 |
| PHASE1 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05593055 | PHASE4 | RECRUITING | Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension |
| NCT02082717 | PHASE4 | TERMINATED | The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis |
| NCT02297048 | PHASE4 | COMPLETED | Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome) |
| NCT02380157 | PHASE4 | COMPLETED | Blood Pressure Regulation - Role of Potassium |
| NCT02653560 | PHASE4 | COMPLETED | Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension |
| NCT04026438 | PHASE4 | COMPLETED | Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT) |
| NCT05411991 | PHASE4 | COMPLETED | Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment |
| NCT06317597 | PHASE4 | UNKNOWN | Efficacy of Short Time Intervals in Split-Dose Bowel Preparation of Oral Sulfate Solution for Colonoscopy |
| NCT04997837 | PHASE3 | RECRUITING | Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma |
| NCT07469722 | PHASE2/PHASE3 | NOT_YET_RECRUITING | POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure |
| NCT00160368 | PHASE3 | UNKNOWN | Effects of Potassium Salts on Blood Pressure and Target Organ Damage |
| NCT00182611 | PHASE3 | COMPLETED | S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer |
| NCT00336947 | PHASE3 | UNKNOWN | S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer |
| NCT00445497 | PHASE3 | UNKNOWN | Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia |
| NCT00660894 | PHASE3 | COMPLETED | Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery |
| NCT00721721 | PHASE3 | COMPLETED | Analyzing Genetic Factors Involved in Blood Pressure Changes Due to Salt and Potassium Intake (The GenSalt Study) |
| NCT01348386 | PHASE2/PHASE3 | COMPLETED | Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum |
| NCT02630992 | PHASE3 | COMPLETED | Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media |
| NCT03006705 | PHASE3 | COMPLETED | Study of Adjuvant ONO-4538 With Resected Gastric Cancer |
| NCT03013010 | PHASE3 | COMPLETED | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy |
| NCT03195647 | PHASE3 | COMPLETED | Pilot Study for the Tight K Study |
| NCT04021381 | PHASE3 | UNKNOWN | Citrate Salts for Stone-free Result After Flexible Ureterorenoscopy for Inferior Calyx Calculi |
| NCT04053816 | PHASE3 | COMPLETED | Prevention of Dysrhythmias on the Cardiac Intensive Care Unit - Does Maintenance of High-normal Serum Potassium Levels Matter |
| NCT04802785 | PHASE2/PHASE3 | UNKNOWN | The Impact of Air Travel on Passenger Cognitive Functions |
| NCT05095467 | PHASE2 | NOT_YET_RECRUITING | HIPEC-AS in Patients With Peritoneal Metastasis of the Stomach or Esophagogastric Junction |
| NCT05138575 | PHASE2 | RECRUITING | SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial |
| NCT05960955 | PHASE2 | RECRUITING | Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
| NCT07238400 | PHASE2 | RECRUITING | Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia |
| NCT07576257 | PHASE2 | NOT_YET_RECRUITING | OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosili-cate in Heart Failure -Extension (OPRA-HF Extension) |
| NCT00000501 | PHASE2 | COMPLETED | Hypertension Prevention Trial (HPT) Feasibility Study |
| NCT00088816 | PHASE2 | UNKNOWN | S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer |
| NCT00134095 | PHASE2 | UNKNOWN | S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer |
| NCT00625937 | PHASE2 | UNKNOWN | Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer |
| NCT00659113 | PHASE2 | UNKNOWN | S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery |
| NCT00974389 | PHASE2 | UNKNOWN | S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery |
| NCT00985556 | PHASE2 | UNKNOWN | Oxaliplatin and S-1 or Oxaliplatin and Capecitabine in Treating Patients With Recurrent, Metastatic, or Unresectable Gastric Cancer |
| NCT00994968 | PHASE2 | UNKNOWN | Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer |
| NCT01074918 | PHASE1/PHASE2 | WITHDRAWN | Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients |
| NCT01682837 | PHASE2 | COMPLETED | Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension |
| NCT02840799 | PHASE2 | COMPLETED | Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
14 molecules share ≥1 primary target. Top 14 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| DALFAMPRIDINE | ChEMBL + PubChem | Phase 4 (approved) | KCNA1, KCNA3 |
| VERAPAMIL | ChEMBL + PubChem | Phase 4 (approved) | KCNA3, KCNA7 |
| Flecainide | PubChem | Approved | KCNA1, KCNA7 |
| CAPSAICIN | ChEMBL + PubChem | Phase 4 (approved) | KCNA1 |
| CLOTRIMAZOLE | ChEMBL + PubChem | Phase 4 (approved) | KCNA3 |
| NIFEDIPINE | ChEMBL + PubChem | Phase 4 (approved) | KCNA1 |
| PAROXETINE | ChEMBL + PubChem | Phase 4 (approved) | KCNA3 |
| DIPHENOXYLATE | ChEMBL | Phase 4 (approved) | KCNA3 |
| CORTISONE | ChEMBL + PubChem | Phase 3 (approved) | KCNA1 |
| TETRYLAMMONIUM | ChEMBL | Phase 2 | KCNA1 |
| Amiodarone | PubChem | Approved | KCNA7 |
| Diltiazem | PubChem | Approved | KCNA1 |
| methoxsalen | PubChem | Approved | KCNA1 |
| Quinidine | PubChem | Approved | KCNA7 |
Related Atlas pages
- Genes: KCNA1, KCNA3, KCNA6, KCNA7, KCNC2
- Drugs: Dalfampridine, Verapamil, Flecainide, Capsaicin, Clotrimazole, Nifedipine, Paroxetine, Diphenoxylate, Cortisone, Amiodarone, Diltiazem, methoxsalen, Quinidine